In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).
Last-line multiple myeloma patients, who have exhausted other treatment options have been responding to oral drug inobrodib in combination with pomalidomide and dexamethasone (pom and dex).
Takeda was awarded conditional EU marketing authorisation of the small molecule drug Ninlaro, overturning the EMA’s negative opinion on its efficacy against Multiple Myeloma (MM).
Takeda will build a high containment production facility at its site in Dublin, Ireland to support the manufacturing of its oncology product Ninlaro (ixazomib).
The open-source study was launched in order to advance understanding of real-world experience with therapies and clinical outcomes in patients with multiple myeloma.
US-based DSM Biologics and MorphoSys are teaming up to manufacture the MOR202 antibody, which has shown considerable promise as a treatment for multiple myeloma (MM).
A deal has been finalised making MDS Pharma Services the preferred
contract research organization (CRO) of the Multiple Myeloma
Research Consortium (MMRC) in the US, with further opportunities in
Europe to follow.
CuraGen and TopoTarget have announced preliminary data suggesting
its small molecule candidate may have potential anti-tumour
activity against haematologic cancer.
A new drug candidate, which targets the protein that protects
cancer cells from dying, has been shown to exhibit increased
anti-tumour activity when combined with an existing cancer
treatments. The data gives hope to those who have...
Infinity Pharmaceuticals announced the initiation of a phase I
clinical trial of the company's lead investigational anticancer
agent for the development of a potential treatment for patients
with multiple myeloma. The compound...
Chiron and the multiple myeloma research consortium have announced
the initiation of a phase I clinical trial for CHIR-258 - the first
drug candidate to undergo clinical study through the MMRC - an
organisation that integrates leading...
Celgene has announced it has submitted a New Drug Application (NDA)
to the Food and Drug Administration (FDA) for its investigational
drug Revlimid, a first in a new class of novel immunomodulatory
drugs, or ImiDs.
A new finding may lead to new treatments for multiple myeloma, an
incurable cancer of immune cells called plasma cells that are
present in the blood and bone marrow.